This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Moretti, R. Articles by Bava, A. Search for Related Content PubMed PubMed Citation Articles by Moretti, R. Articles by Bava, A. Social Bookmarking                         What's this?

Olanzapine as a possible treatment for anxiety due to vascular dementia: An open study

Dipartimento di Fisiologia e Patologia, Università di Trieste; Dipartimento di Medicina Clinica e Neurologia, UCO di Neurologia, Sezione Disturbi Cognitivi, Università di Trieste, Trieste, Italy.

Paola Torre, MD

Rodolfo M. Antonello, MD

Tatiana Cattaruzza, MD

Giuseppe Cazzato, MD

Dipartimento di Medicina Clinica e Neurologia, UCO di Neurologia, Sezione Disturbi Cognitivi, Università di Trieste, Trieste, Italy.

Antonio Bava, MD

Dipartimento di Fisiologia e Patologia, Università di Trieste, Trieste, Italy.

Disabilities caused by behavioral problems can be potentially devastating in cognitively impaired patients. These behavioral symptoms can be a major cause of stress, anxiety, and concern for caregivers. While psychotropic drugs are frequently used to control these symptoms, they can be accompanied by significant side effects, which include sedation, disinhibition, depression, falls, incontinence, parkinsonism, and akathisias. Agitation is a major problem in older patients with dementia. Agitation and aggression have always been difficult behaviors to manage, and when it is severe, agitation can be a behavioral emergency that requires urgent and immediate intervention.

This six-month study included a group of 94 outpatients (48 men and 46 women) who had a diagnosis of subcortical vascular dementia (VaD). To be eligible for the study, patients needed a score of at least 3 for agitation/ aggression on the Neuropsychiatric Inventory (NPI), suggesting at least moderate frequency and/or severity, and 0 for delusions and hallucinations. Patients were divided into two homogenous groups. Group A received olanzapine (2.5-5 mg/day) and Group B received bromazepam (0.25 percent, 15 drops, three times per day). Patients in both groups were allowed to continue any previous therapy. Patients receiving olanzapine at an average dose of 3.21 ± 1.02 mg/day showed statistically significant improvement on the anxiety rating compared with those receiving bromazepam. Our patients had a host of medical conditions and received numerous concomitant medications. Given the potential complications associated with these therapeutic agents, these patients tolerated olanzapine quite well. It appeared that adverse events, particularly somnolence, postural instability, and postural hypotension, were mild and transient. Moreover, no anticholinerigic effect was registered. These findings suggest that olanzapine could be a safe and effective treatment for anxiety in cognitively impaired patients.

Key Words: agitation • behavior • vascular dementia • BEHAVE-AD • NPI

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 19, No. 2, 81-88 (2004)
DOI: 10.1177/153331750401900215


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. L. Onor, M. Saina, and E. Aguglia Efficacy and Tolerability of Quetiapine in the Treatment of Behavioral and Psychological Symptoms of Dementia American Journal of Alzheimer's Disease and Other Dementias, January 1, 2007; 21(6): 448 - 453. [Abstract] [PDF]